Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$692.79B | 62.7x | 0.76 | US$771.71 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.4% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$393.87B | 17.5x | -0.44 | US$163.70 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$334.31B | 80.6x | -2.68 | US$189.26 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.1% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$286.56B | 17.6x | 1.01 | US$64.31 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.6% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$258.55B | 26.3x | -0.89 | US$324.56 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$258.55B | 26.3x | -0.89 | US$40.08 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$256.40B | 11.7x | 0.26 | US$282.65 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$222.93B | 16.9x | -1.32 | US$118.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$222.93B | 16.9x | -1.3 | US$114.25 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.7% Downside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$215.17B | 15.1x | 0.1 | US$123.67 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$214.04B | 27.6x | 1.22 | US$142.02 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$214.04B | 27.6x | 1.22 | US$68.79 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.1% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$200.78B | 11.6x | 0.02 | US$79.96 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.1% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$185.88B | 74.3x | 3.21 | US$518.62 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$158.49B | 26.8x | 0.48 | US$294.76 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.5% Upside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$156.57B | 24.1x | 2.63 | US$414.75 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.2% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$153.33B | 75.2x | 5 | US$103.64 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$148.81B | 51.9x | -3.35 | US$389.40 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.9% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$139.12B | 17.6x | 0.01 | US$24.47 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.9% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$136.01B | 36.6x | -2.94 | US$190.05 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$134.62B | 22.6x | 0.02 | US$108.22 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.9% Upside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$130.71B | 46.8x | 48.6 | US$141.50 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.3% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Pharmaceuticals | US$118.08B | -119.6x | 0.96 | US$459.81 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$117.72B | 16.7x | 0.41 | US$48.32 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.7% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$114.81B | 24.7x | 0.8 | US$89.61 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$96.38B | 17.8x | 0.1 | US$47.36 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.4% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$88.80B | 27.6x | 1.81 | US$709.80 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$86.88B | 15.9x | 1.23 | US$361.12 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$81.13B | 29.5x | 2.55 | US$83.82 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | US$79B | 16.2x | 0.34 | US$295.71 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | US$78.38B | 14.8x | -0.57 | US$61.96 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.4% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$77.44B | 27.9x | 1.08 | US$23.19 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$73.05B | 17.5x | -0.6 | US$17.15 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$73.05B | 17.5x | -0.6 | US$36.31 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.3% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$66.16B | 26.5x | 3.62 | US$148.60 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30% Upside | Upgrade to Pro+ | |
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | US$62.60B | 12.9x | -0.65 | US$277.09 | -8.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$59.75B | 26.4x | US$26.68 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Regeneron Pharma | NASDAQ | Healthcare | Pharmaceuticals | US$57.33B | 13x | 0.78 | US$542.52 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.9% Upside | Upgrade to Pro+ | |
Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | US$56.77B | 33.9x | -5.64 | US$292.87 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.1% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$55.91B | 17.1x | 4.97 | US$25.83 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.5% Upside | Upgrade to Pro+ | |
Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | US$51.26B | 34.4x | 2.46 | US$178.85 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.3% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$50.22B | 58x | US$70.86 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | ||
Veeva Systems A | NYSE | Healthcare | Healthcare Equipment & Supplies | US$46.13B | 58.5x | 1.49 | US$282.29 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.5% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$46.06B | 63.5x | -2.46 | US$26.70 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$46.06B | 63.5x | -2.46 | US$14.43 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$45.13B | 23.1x | 0.46 | US$24 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.8% Upside | Upgrade to Pro+ | |
Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | US$44.87B | 31.6x | 0.15 | US$76.49 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.3% Upside | Upgrade to Pro+ | |
Alcon | NYSE | Healthcare | Healthcare Equipment & Supplies | US$43.38B | 38.5x | 5.77 | US$87.35 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$43.21B | 23.7x | 0.57 | US$9.60 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.9% Upside | Upgrade to Pro+ | |
Hoya Corp | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$42.19B | 31.6x | 2.43 | US$123.23 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ |